Table 4. NCI-60 Screening Results for Clavatadines C–E (3–5)^a.

cell type /compound	CCRF-CEM (leukemia)	K-262 (leukemia)	A-549 (lung)	NCI-H522 (lung)	HCT-15 (colon)	SF-268 (CNS)	SNB-75 (CNS)	OVCAR-3 (ovarian)	MCF-7 (breast)	MDA-MB-468 (breast)
Clavatadine C (3)	96	95	110b	87	105	95	107	103	98c	111
Clavatadine D (4)	62	62	110	69	73	92	98	80	80	76
Clavatadine E (5)	102	105	108	96	103	68	80	97	104	108

^aNumbers reflect mean growth percent. 100 percent indicates no effect.

^bRef (10) reported 39 ± 7% cell viability after 24 h upon exposure of this cell line to compound 3 [10 μM].

^cRef (10) reported 30 ± 5% cell viability after 24 h upon exposure of this cell line to compound 3 [10 μM].